JP6823175B2 - 二重特異性抗ｈｅｒ２抗体 - Google Patents

二重特異性抗ｈｅｒ２抗体 Download PDF

Info

Publication number
JP6823175B2
JP6823175B2 JP2019524501A JP2019524501A JP6823175B2 JP 6823175 B2 JP6823175 B2 JP 6823175B2 JP 2019524501 A JP2019524501 A JP 2019524501A JP 2019524501 A JP2019524501 A JP 2019524501A JP 6823175 B2 JP6823175 B2 JP 6823175B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019524501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528779A5 (https=
JP2019528779A (ja
Inventor
フォン リー
フォン リー
ポーイェン チャン
ポーイェン チャン
ペイ イェー
ペイ イェー
チエン チャオ
チエン チャオ
スーチア ホアン
スーチア ホアン
チュンヤン チン
チュンヤン チン
Original Assignee
ベイジン マブワークス バイオテック カンパニー，リミティド
ベイジン マブワークス バイオテック カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジン マブワークス バイオテック カンパニー，リミティド, ベイジン マブワークス バイオテック カンパニー，リミティド filed Critical ベイジン マブワークス バイオテック カンパニー，リミティド
Publication of JP2019528779A publication Critical patent/JP2019528779A/ja
Publication of JP2019528779A5 publication Critical patent/JP2019528779A5/ja
Application granted granted Critical
Publication of JP6823175B2 publication Critical patent/JP6823175B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019524501A 2016-07-22 2017-07-21 二重特異性抗ｈｅｒ２抗体 Expired - Fee Related JP6823175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610584242.9 2016-07-22
CN201610584242.9A CN107446045A (zh) 2016-07-22 2016-07-22 一种抗her2的抗体、其药物组合物及用途
US15/461,732 2017-03-17
US15/461,732 US9745382B1 (en) 2016-07-22 2017-03-17 Bispecific anti-HER2 antibody
PCT/CN2017/093816 WO2018014864A1 (en) 2016-07-22 2017-07-21 Bispecific anti-her2 antibody

Publications (3)

Publication Number Publication Date
JP2019528779A JP2019528779A (ja) 2019-10-17
JP2019528779A5 JP2019528779A5 (https=) 2019-12-12
JP6823175B2 true JP6823175B2 (ja) 2021-01-27

Family

ID=59654118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524501A Expired - Fee Related JP6823175B2 (ja) 2016-07-22 2017-07-21 二重特異性抗ｈｅｒ２抗体

Country Status (7)

Country Link
US (1) US9745382B1 (https=)
EP (1) EP3487888A4 (https=)
JP (1) JP6823175B2 (https=)
CN (2) CN107446045A (https=)
AU (1) AU2017298251B2 (https=)
CA (1) CA3031330C (https=)
WO (1) WO2018014864A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
ES2958933T3 (es) 2018-03-13 2024-02-16 Zymeworks Bc Inc Conjugados de anticuerpo biparatópico anti-HER2-fármaco y métodos de uso
WO2020000452A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种靶向人NGL基因的新型RNAi干扰片段、RNAi载体及其制备方法和其应用
WO2020000458A1 (zh) * 2018-06-29 2020-01-02 深圳市博奥康生物科技有限公司 一种特异靶向人NGL基因的gRNA导向序列及其应用
KR20210074279A (ko) * 2018-08-22 2021-06-21 데날리 테라퓨틱스 인크. 항-her2 폴리펩타이드 및 이의 사용방법
AU2018438163A1 (en) * 2018-08-29 2021-04-01 United Biopharma Inc Afucosylated antibodies and manufacture thereof
EP3988574A4 (en) * 2019-02-03 2022-10-12 Shanghai Bao Pharmaceuticals Co., Ltd. AGAINST HER2 BI-SPECIFIC ANTIBODIES AND THEIR USE
CN111670201A (zh) * 2019-03-01 2020-09-15 荣昌生物制药(烟台)股份有限公司 一种Her2伴随诊断免疫组化检测抗体及其应用
CN111848805B (zh) * 2019-04-30 2023-05-05 非同（成都）生物科技有限公司 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
TWI867218B (zh) * 2020-04-30 2024-12-21 大陸商正大天晴藥業集團股份有限公司 靶向her2的抗原結合建構體及用途
WO2021247718A1 (en) * 2020-06-03 2021-12-09 The Broad Institute, Inc. Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用
CN114539413A (zh) * 2020-11-25 2022-05-27 三生国健药业（上海）股份有限公司 结合her2的多价双特异性抗体、其制备方法和用途
JP2024525624A (ja) * 2021-07-05 2024-07-12 チャンスー アルファマブ バイオファーマシューティカルズ カンパニー，リミテッド 抗体薬物コンジュゲート及びその使用
CN113817065B (zh) * 2021-09-06 2023-04-18 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
CN120051495A (zh) * 2022-08-05 2025-05-27 詹森生物科技公司 用于治疗脑肿瘤的cd98结合构建体
EP4565330A1 (en) * 2022-08-05 2025-06-11 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
JP2026504928A (ja) * 2023-01-20 2026-02-10 ワシントン・ユニバーシティ Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法
WO2024183623A1 (zh) * 2023-03-03 2024-09-12 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2024183622A1 (zh) * 2023-03-03 2024-09-12 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2025124463A1 (zh) * 2023-12-12 2025-06-19 上海宝济药业股份有限公司 抗her2的双特异性抗体及其应用
CN118206662A (zh) * 2024-05-14 2024-06-18 中国人民解放军军事科学院军事医学研究院 一种靶向Her2的新型单克隆抗体及其应用
WO2026077405A1 (zh) * 2024-10-11 2026-04-16 烟台蓝纳成生物技术股份有限公司 一种抗her2抗体、抗体核素偶联物及其应用
CN119462959B (zh) * 2024-10-24 2025-12-19 南京元迈细胞生物科技有限公司 嵌合抗原受体及其修饰的细胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
AR095774A1 (es) * 2013-04-05 2015-11-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
HRP20250551T1 (hr) * 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
EP3327038B1 (en) 2013-12-20 2020-09-23 F. Hoffmann-La Roche AG Bispecific her2 antibodies and methods of use
MX2016012830A (es) * 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
CN105017421B (zh) 2014-04-16 2017-12-26 中国人民解放军海军总医院 一种抗her2双特异性抗体及其制备方法与应用
JP2017513901A (ja) * 2014-04-25 2017-06-01 ジェネンテック， インコーポレイテッド トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
CN110655582B (zh) * 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物

Also Published As

Publication number Publication date
AU2017298251A1 (en) 2019-02-14
EP3487888A1 (en) 2019-05-29
CN109715671B (zh) 2020-08-21
AU2017298251B2 (en) 2020-02-06
EP3487888A4 (en) 2020-04-01
WO2018014864A1 (en) 2018-01-25
CN107446045A (zh) 2017-12-08
US9745382B1 (en) 2017-08-29
CA3031330A1 (en) 2018-01-25
CA3031330C (en) 2020-04-28
CN109715671A (zh) 2019-05-03
JP2019528779A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
JP6823175B2 (ja) 二重特異性抗ｈｅｒ２抗体
AU2022213913B2 (en) Single-domain antibody against cd16a and use thereof
JP7082620B2 (ja) 抗ｐｄ１モノクローナル抗体、その医薬組成物およびその使用
US10377833B2 (en) Bispecific anti-HER2 antibody
CN114478768B (zh) 抗cd73的抗体及其用途
JP2019533475A (ja) 抗ｃｔｌａ４−抗ｐｄ−１二機能性抗体、その医薬組成物および使用
WO2023151693A1 (zh) 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途
US12540183B2 (en) Anti-CD4 antibodies
JP2022527935A (ja) Ｃｄ３結合分子
KR20240039006A (ko) 신규 항-sirpa 항체
CN118251419A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
WO2024051223A1 (zh) 药物组合及用途
WO2023246247A1 (zh) 药物组合物及其用途
WO2023138677A1 (en) Novel anti-lag3 antibodies and derivative products
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products
US20200087410A1 (en) Humanized anti-cd40 antibodies
CN119613559B (zh) 药物组合及用途
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
CN119735686B (zh) 一种针对her2抗原的人源化抗体及其应用
JP2022520649A (ja) Ｅｇｆｒ、ｈｅｒ２及びｈｅｒ３に結合する結合部分の組み合わせ
WO2025201450A1 (zh) 药物组合及用途
WO2024183791A1 (zh) 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途
HK40123044A (zh) 药物组合及用途
HK40123044B (zh) 药物组合及用途
HK40109390A (zh) 药物组合及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191029

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191029

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210107

R150 Certificate of patent or registration of utility model

Ref document number: 6823175

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees